Exposure-Response Of Quizartinib Efficacy In Patients With Relapsed/Refractory Aml

Dongwoo Kang,Julie Passarell,Malaz A Abutarif,Jeanne Mendell,Ophelia Yin

BLOOD（2019）

引用 0|浏览5

暂无评分

摘要

Introduction: Quizartinib is a once-daily, oral, highly potent and selective FLT3 inhibitor that has shown clinical activity in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3 internal tandem duplications in the phase 3 QuANTUM-R trial (Cortes et al, Lancet Oncol 2019; NCT02039726). In this analysis, exposure-response relationships of select efficacy endpoints of quizartinib were evaluated.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要